From Drugs.com: " When used at high doses in dose-ranging studies in patients with acute leukemia, Fludarabine Phosphate for Injection, USP was associated with severe neurologic effects, including blindness, coma, and death. "
Sad events---but--what did the patients die of? Sepsis? An acute ischemic event? Pulmonary emboli? GI bleed? Acute renal failure? Acute CNS event? Given previous positive studies, one hesitates to blame Juno's 'T-cell primer.'
The importance of their Dana-Farber-run trial of GMI-1271 in treatment-naive AML can't be over-emphasized. Somehow, this has occurred under the radar in this relatively illiquid stock. To be expected: HUGE increase in value if it works, albeit disastrous tanking if not:-)
So--now we can surmise just why GLYC dropped, despite the positive FDA decision on fast-tracking. One can be suspicious that someone 'smelled' the shelf offer (with its associated dilution)--and bailed out. Of course, that doesn't mean that the stock price won't--at some time--take off.
Is there any space available next to Madoff's cubicle??
Science Translational Medicine has published preclinical research in its May 25 issue pointing to a potential clinical application for GMI-1271 in the treatment of breast cancer. The published study details research in an in vivo model that showed the company’s drug candidate, GMI-1271, a novel E-selectin antagonist, inhibits breast cancer metastasis.
Without getting too enthusiastic, I'd presume that given GLYC's pipeline, initial positive results re: sickle crisis and AML--and proprietary technology----it's being evaluated for a takeover. Several large Pharma's ( including PFE) are sitting on lots of cash. Let me start by suggesting a price of $25/share.
Their preclinical studies on use of GM-1271 to treat Tylenol-associated liver toxicity are significant and apparently they are exploring myriad OTHER uses (as well as for AML). Stay tuned.